anmelden
SMI Expanded
1.950,54
PKT
+8,48
PKT
+0,44
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu SMI Expanded-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 16.10.12 | ABB (Asea Brown Boveri) hold | Société Générale Group S.A. (SG) | |
| 16.10.12 | Kühne + Nagel International equal-weight | Morgan Stanley | |
| 16.10.12 | Kühne + Nagel International hold | Deutsche Bank AG | |
| 16.10.12 | Nestlé overweight | Morgan Stanley | |
| 16.10.12 | Kühne + Nagel International buy | Nomura | |
| 16.10.12 | Logitech outperform | Exane-BNP Paribas SA | |
| 16.10.12 | Clariant buy | Vontobel Research | |
| 16.10.12 | UBS neutral | Macquarie Research | |
| 16.10.12 | Novartis outperform | Credit Suisse Group | |
| 15.10.12 | UBS outperform | Exane-BNP Paribas SA | |
| 15.10.12 | Nestlé neutral | HSBC | |
| 15.10.12 | UBS neutral | Exane-BNP Paribas SA | |
| 15.10.12 | Nestlé outperform | Cheuvreux SA | |
| 15.10.12 | Nestlé neutral | Goldman Sachs Group Inc. | |
| 15.10.12 | Givaudan hold | Vontobel Research | |
| 15.10.12 | Kühne + Nagel International neutral | Sarasin Research | |
| 15.10.12 | Roche buy | Sarasin Research | |
| 15.10.12 | Kühne + Nagel International hold | Vontobel Research | |
| 15.10.12 | Clariant buy | Sarasin Research | |
| 15.10.12 | Clariant buy | Vontobel Research | |
| 15.10.12 | Swiss Life neutral | Goldman Sachs Group Inc. | |
| 12.10.12 | Novartis outperform | Credit Suisse Group | |
| 12.10.12 | Zurich Insurance buy | Goldman Sachs Group Inc. | |
| 12.10.12 | Swiss Re sell | Goldman Sachs Group Inc. | |
| 12.10.12 | Novartis buy | Nomura | |
| 12.10.12 | SGS SA buy | Vontobel Research | |
| 12.10.12 | Roche outperform | Exane-BNP Paribas SA | |
| 12.10.12 | Holcim outperform | Exane-BNP Paribas SA | |
| 12.10.12 | Holcim outperform | Exane-BNP Paribas SA | |
| 12.10.12 | UBS outperform | Credit Suisse Group | |
| 12.10.12 | Novartis reduce | Vontobel Research | |
| 12.10.12 | Givaudan outperform | Exane-BNP Paribas SA | |
| 12.10.12 | Roche neutral | Nomura | |
| 12.10.12 | Roche outperform | Credit Suisse Group | |
| 12.10.12 | Swiss Re buy | Société Générale Group S.A. (SG) | |
| 12.10.12 | Novartis buy | UBS AG | |
| 11.10.12 | ABB (Asea Brown Boveri) outperform | Exane-BNP Paribas SA | |
| 11.10.12 | Roche buy | Deutsche Bank AG | |
| 11.10.12 | Novartis buy | Deutsche Bank AG | |
| 11.10.12 | Novartis buy | UBS AG |